Reaching a $2.5B valuation marks a major milestone for the startup. Its platform gives users deep, personalized biological analysis. Investors view this as the next evolution of healthcare.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
